Equities research analysts at Cowen and Company began coverage on shares of Kura Oncology, Inc. (NASDAQ:KURA) in a research note issued to investors on Thursday. The firm set an “outperform” rating on the stock.

Several other equities analysts have also issued reports on KURA. Cann reaffirmed a “buy” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Monday, May 15th. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Thursday, May 18th. Oppenheimer Holdings, Inc. set a $16.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a report on Wednesday, June 14th. Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price target (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $14.15.

Kura Oncology (KURA) opened at 11.80 on Thursday. The company’s market capitalization is $235.86 million. Kura Oncology has a 52-week low of $4.00 and a 52-week high of $13.80. The company has a 50-day moving average price of $7.97 and a 200 day moving average price of $8.71.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Equities research analysts anticipate that Kura Oncology will post ($1.55) earnings per share for the current year.

WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/10/kura-oncology-inc-kura-research-coverage-started-at-cowen-and-company.html.

Large investors have recently bought and sold shares of the company. State of Wisconsin Investment Board acquired a new stake in shares of Kura Oncology during the second quarter worth $102,000. Oppenheimer & Co. Inc. lifted its stake in shares of Kura Oncology by 14.7% during the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after buying an additional 1,600 shares during the period. Segantii Capital Management Ltd acquired a new stake in shares of Kura Oncology during the first quarter worth $120,000. Rhumbline Advisers acquired a new stake in shares of Kura Oncology during the second quarter worth $131,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Kura Oncology during the second quarter worth $142,000. Institutional investors and hedge funds own 39.07% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.